3D ProLiFiler™ Spheroid Cancer Cell Panel Screening Service

The three-dimensional (3D) ProLiFilerTM spheroid panel screening service enables scientists to analyze the therapeutic potency and tumor-penetrating efficacy of new anti-cancer compounds on 3D spheroids grown from a panel of 40 distinctive cell lines derived from 13 tumor entities. This service provides an efficient way to check for compound efficacy against 40 common tumor cell lines.

3D tumor spheroids, also known as cancer spheroids, are composed of tumor cells in various proliferative and metabolic states and have demonstrated to mimic complex physiological tumor processes like tumorigenesis, microenvironment, heterogeneity, and tumor-immune interaction. Testing cancer drug candidates on a panel of 3D spheroids grown from distinct tumor cell lines with important clinical mutations yields high-quality data from a physiologically relevant in vitro assay format, making it a valuable tool for lead candidate selection for further in vivo studies.

3D ProLiFilerTM spheroid cancer cell panel screening key advantages:

  • Evaluate drug responses in using a 3D model across 40 cell lines to better understand compound effectiveness and prioritize the most suitable and potent compounds before moving to in vivo studies.
  • A more physiologically relevant model that mimics in vivo tumor biology, signaling cascades, and tumor progression with reproduced gradients of oxygenation, nutrition, and pH.
  • 3D spheroids reflect the tumor microenvironment by modeling 3D cell-cell attachment, interaction, and cell-ECM interactions. 

Distribution of 3D ProLiFiler™ Spheroid Panel Screen Entities

The 3D ProLiFilerTM spheroid panel screening service has 40 cell lines derived from 13 distinct entities with clinically important oncogenic mutations available for your next cell panel screening project.

Please inquire to obtain the list of included cell lines.

3D ProLiFiler Entities

3D Spheroid Panel Screen Details

Assay Description

Assay Description

3D ProLiFiler Assay

Tumor cells are incubated for 2 days in ultra-low attachment surface plates (384 well format) , shortly spun down, and allowed to autonomously self-assemble to form spheroids. The test compound is added and incubate for 6 days. Finally, cell plates are equilibrated to room temperature, and the viability of cells is determined with the CellTiter-Glo luminescent reagent based on the amount of ATP present.

Case Study

Case study: Characterization of MEK-inhibitor in 3D and 2D cell culture format

Case study: Comparison of 2D and 3D spheroid cell screening using a MEK inhibitor

Characterization of MEK-inhibitors in 3D cell panel format: Higher potency was demonstrated by a reference clinical MEK inhibitor in a 3D screening assay vs. a 2D format, ultimately targeting the MAPK kinase signaling cascade. MEK-Inhibitors show increased activity on cells, confirming different physiological situations of cells in 3D, while control proteasome inhibitor activity shows no effect. Black: 2D data, Red = 3D data.

Join the next screen - the next 3D ProLiFilerTM screening schedule starts early September 2023.
If you are interested in taking part please contact us.